Skip to content

Hepatitis C testing rate low and knowledge of the infection poor in the US "baby boomer" generation

Standard hepatitis C therapy improves insulin resistance in HIV/hepatitis C co-infected patients

BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis

Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir

Promising findings for therapeutic hepatitis C vaccine TG4040

Depression and pegylated interferon: doctors look at screening strategies and treatment

Co-infection with hepatitis C increases mortality risk by 50% for patients with AIDS

Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity

Josep Llovet, University of Barcelona [Photo by Liz Highleyman, hivandhepatitis.com]

GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks

Kris Kowdley, Virginia Mason Medical Center, Seattle [Photo by Liz Highleyman, hivandhepatitis.com]